Effect of hot flushes on vascular function: A randomized controlled trial

Obstetrics and Gynecology

Volumn 114, Issue 4, 2009, Pages 777-785

  Tuomikoski, Pauliina ^a,b   Ebert, Pia ^a,b   Groop, Per Henrik ^a,b   Haapalahti, Petri ^a,b   Hautamäki, Hanna ^a,b   Rönnback, Mats ^a,b   Ylikorkala, Olavi ^a,b   Mikkola, Tomi S ^a,b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b FOLKHÄLSAN INSTITUTE OF GENETICS   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; GLYCERYL TRINITRATE; MEDROXYPROGESTERONE ACETATE; PLACEBO; SALBUTAMOL;

ADULT; ARTERIAL STIFFNESS; ARTERY ENDOTHELIUM; ARTICLE; BLOOD VESSEL REACTIVITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ENDOTHELIUM; EQUIPMENT; FEMALE; HEART VENTRICLE EJECTION; HORMONAL THERAPY; HOT FLUSH; HUMAN; MENOPAUSE; POSTMENOPAUSE; PRIORITY JOURNAL; PULSE WAVE; RANDOMIZED CONTROLLED TRIAL; SYSTOLE; VASCULARIZATION;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ALBUTEROL; ENDOTHELIUM, VASCULAR; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HOT FLASHES; HUMANS; MEDROXYPROGESTERONE ACETATE; MIDDLE AGED; NITROGLYCERIN; PULSATILE FLOW; STROKE VOLUME;

EID: 70349664004     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/AOG.0b013e3181b6f268     Document Type: Article

References (43)

1. Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117:1016-1037
2. Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000;133:933-941
3. Hodis HN, Mack WJ. Postmenopausal hormone therapy and cardiovascular disease in perspective. Clin Obstet Gynecol 2008;51:564-580
4. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) research group. JAMA 1998;280:605-613
5. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized controlled trial. JAMA 2002;288:321-333
6. Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523-534
7. van der Schouw YT, Grobbee DE. Menopausal complaints, oestrogens, and heart disease risk: an explanation for discrepant findings on the benefits of post-menopausal hormone therapy. Eur Heart J 2005;26:1358-1361
8. Mendelsohn ME, Karas RH. HRT and the young at heart. N Engl J Med 2007;356:2639-2641
9. Freedman RR. Pathophysiology and treatment of menopausal hot flashes. Semin Reprod Med 2005;23:117-125
10. Deecher DC, Dorries K. Understanding the pathophysiology of vasomotor symptoms (hot flushes and night sweats) that occur in perimenopause, menopause, and postmenopause life stages. Arch Womens Ment Health 2007;10:247-257
11. Thurston RC, Sutton-Tyrrell K, Everson-Rose SA, Hess R, Matthews KA. Hot flashes and subclinical cardiovascular disease: findings from the Study of Women's Health Across the Nation Heart Study. Circulation 2008;118:1234-1240
12. Gast GC, Grobbee DE, Pop VJ, Keyzer JJ, Wijnands-van Gent CJ, Samsioe GN, et al. Menopausal complaints are associated with cardiovascular risk factors. Hypertension 2008;51:1492-1498
13. Crandall CJ, Zheng Y, Crawford SL, Thurston RC, Gold EB, Johnston JM, et al. Presence of vasomotor symptoms is associated with lower bone mineral density: a longitudinal analysis. Menopause 2009;16:239-246
14. Tuomikoski P, Ebert P, Groop PH, Haapalahti P, Hautamäki H, Rönnback M, et al Evidence for a role of hot flushes in vascular function in recently postmenopausal women. Obstet Gynecol 2009;113:902-908
15. Notelovitz M, Lenihan JP, McDermott M, Kerber IJ, Nanavati N, Arce J. Initial 17beta-estradiol dose for treating vasomotor symptoms. Obstet Gynecol 2000;95:726-731
16. Sloan JA, Loprinzi CL, Novotny PJ, Barton DL, Lavasseur BI, Windschitl H. Methodologic lessons learned from hot flash studies. J Clin Oncol 2001;19:4280-4290
17. Panay N, Ylikorkala O, Archer DF, Gut R, Lang E. Ultra-lowdose estradiol and norethisterone acetate: Effective menopausal symptom relief. Climacteric 2007;10:120-131
18. Rönnback M, Lampinen K, Groop PH, Kaaja R. Pulse wave reflection in currently and previously preeclamptic women. Hypertens Pregnancy 2005;24:171-180
19. Nelson RE, Grebe SK, OKane DJ, Singh RJ. Liquid chromatography- tandem mass spectrometry assay for simultaneous measurement of estradiol and estrone in human plasma. Clin Chem 2004;50:373-384
20. Wilkinson IB, Hall IR, MacCallum H, Mackenzie IS, McEniery CM, van der Arend BJ, et al. Pulse-wave analysis: clinical evaluation of a noninvasive, widely applicable method for assessing endothelial function. Arterioscler Thromb Vasc Biol 2002;22:147-152
21. Mackenzie IS, Wilkinson IB, Cockcroft JR. Assessment of arterial stiffness in clinical practice. QJM 2002;95:67-74.
22. O'Rourke MF, Adji A. An updated clinical primer on large artery mechanics: implications of pulse waveform analysis and arterial tonometry. Curr Opin Cardiol 2005;20:275-281
23. Davies JI, Struthers AD. Pulse wave analysis and pulse wave velocity: a critical review of their strengths and weaknesses. J Hypertens 2003;21:463-472
24. Wilkinson IB, MacCallum H, Cockcroft JR, Webb DJ. Inhibition of basal nitric oxide synthesis increases aortic augmentation index and pulse wave velocity in vivo. Br J Clin Pharmacol 2002;53:189-192
25. Wilkinson IB, Mohammad NH, Tyrrell S, Hall IR, Webb DJ, Paul VE, et al. Heart rate dependency of pulse pressure amplification and arterial stiffness. Am J Hypertens 2002;15: 24-30.
26. Hayward CS, Kraidly M, Webb CM, Collins P. Assessment of endothelial function using peripheral waveform analysis: a clinical application. J Am Coll Cardiol 2002;40:521-528
27. Törmälä R, Appt S, Clarkson TB, Groop PH, Rönnback M, Ylikorkala O, et al. Equol production capability is associated with favorable vascular function in postmenopausal women using tibolone; no effect with soy supplementation. Atherosclerosis 2008;198:174-178
28. Nichols WW. Clinical measurement of arterial stiffness obtained from noninvasive pressure waveforms. Am J Hypertens 2005;18:3S-10S.
29. Teede HJ. Sex hormones and the cardiovascular system: effects on arterial function in women. Clin Exp Pharmacol Physiol 2007;34:672-676
30. Koledova VV, Khalil RA. Sex hormone replacement therapy and modulation of vascular function in cardiovascular disease. Expert Rev Cardiovasc Ther 2007;5:777-789
31. Najjar SS, Scuteri A, Lakatta EG. Arterial aging: is it an immutable cardiovascular risk factor? Hypertension 2005;46: 454-462
32. Lakoski SG, Herrington DM. Effects of hormone therapy on C-reactive protein and IL-6 in postmenopausal women: a review article. Climacteric 2005;8:317-326
33. Pradhan AD, Manson JE, Rossouw JE, Siscovick DS, Mouton CP, Rifai N, et al. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study. JAMA 2002;288:980-987
34. Wakatsuki A, Okatani Y, Ikenoue N, Fukaya T. Effect of medroxyprogesterone acetate on vascular inflammatory markers in postmenopausal women receiving estrogen. Circulation 2002;105:1436-1439
35. Saucedo R, Rico G, Basurto L, Ochoa R, Zarate A. Transdermal estradiol in menopausal women depresses interleukin-6 without affecting other markers of immune response. Gynecol Obstet Invest 2002;53:114-117
36. Sumino H, Ichikawa S, Kasama S, Takahashi T, Kumakura H, Takayama Y, et al. Different effects of oral conjugated estrogen and transdermal estradiol on arterial stiffness and vascular inflammatory markers in postmenopausal women. Atherosclerosis 2006;189:436-442
37. Silvestri A, Gebara O, Vitale C, Wajngarten M, Leonardo F, Ramires JA, et al. Increased levels of C-reactive protein after oral hormone replacement therapy may not be related to an increased inflammatory response. Circulation 2003;107: 3165-3169
38. Yasui T, Uemura H, Tomita J, Miyatani Y, Yamada M, Kuwahara A, et al. Association of interleukin-8 with hot flashes in premenopausal, perimenopausal, and postmenopausal women and bilateral oophorectomized women. J Clin Endocrinol Metab 2006;91:4805-4808
39. Clarkson TB, Appt SE. MPA and postmenopausal coronary artery atherosclerosis revisited. Steroids 2003;68:941-951
40. Sitruk-Ware R. New hormonal therapies and regimens in the postmenopause: routes of administration and timing of initiation. Climacteric 2007;10:358-370
41. Yeboah J, Reboussin DM, Waters D, Kowalchuk G, Herrington DM. Effects of estrogen replacement with and without medroxyprogesterone acetate on brachial flow-mediated vasodilator responses in postmenopausal women with coronary artery disease. Am Heart J 2007;153:439-444
42. Skouby SO, Gram J, Andersen LF, Sidelmann J, Petersen KR, Jespersen J. Hormone replacement therapy: estrogen and progestin effects on plasma C-reactive protein concentrations. Am J Obstet Gynecol 2002;186:969-977
43. Hermsmeyer RK, Thompson TL, Pohost GM, Kaski JC. Cardiovascular effects of medroxyprogesterone acetate and progesterone: a case of mistaken identity? Nat Clin Pract Cardiovasc Med 2008;5:387-395